Literature DB >> 19005225

Modeling single and repeated dose pharmacokinetics of PFOA in mice.

Inchio Lou1, John F Wambaugh, Christopher Lau, Roger G Hanson, Andrew B Lindstrom, Mark J Strynar, R Dan Zehr, R Woodrow Setzer, Hugh A Barton.   

Abstract

Perfluorooctanoic acid (PFOA) displays complicated pharmacokinetics in that serum concentrations indicate long half-lives despite which steady state appears to be achieved rapidly. In this study, serum and tissue concentration time-courses were obtained for male and female CD1 mice after single, oral doses of 1 and 10 mg/kg of PFOA. When using one- and two-compartment models, the pharmacokinetics for these two dosages are not consistent with serum time-course data from female CD1 mice administered 60 mg/kg, or with serum concentrations following repeated daily doses of 20 mg/kg PFOA. Some consistency between dose regimens could be achieved using the saturable resorption model of Andersen et al. In this model PFOA is cleared from the serum into a filtrate compartment from which it is either excreted or resorbed into the serum by a process presumed transporter mediated with a Michaelis-Menten form. Maximum likelihood estimation found a transport maximum of T(m) = 860.9 (1298.3) mg/l/h and half-maximum concentration of K(T) = 0.0015 (0.0022) mg/l where the estimated standard errors (in parentheses) indicated large uncertainty. The estimated rate of flow into and out of the filtrate compartment, 0.6830 (1.0131) l/h was too large to be consistent with a biological interpretation. For these model parameters a single dose greater than 40 mg/kg, or a daily dose in excess of 5 mg/kg were necessary to observe nonlinear pharmacokinetics for PFOA in female CD1 mice. These data and modeling analyses more fully characterize PFOA in mice for purposes of estimating internal exposure for use in risk assessment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005225     DOI: 10.1093/toxsci/kfn234

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  23 in total

1.  Developmental toxicology: new directions workshop: refining testing strategies and study designs.

Authors:  Kimberly C Brannen; Suzanne E Fenton; Deborah K Hansen; Wafa Harrouk; James H Kim; Dana Shuey
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2011-10

Review 2.  Endocrine disruptors and the breast: early life effects and later life disease.

Authors:  Madisa B Macon; Suzanne E Fenton
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-02-17       Impact factor: 2.673

3.  Prenatal perfluorooctanoic acid exposure in CD-1 mice: low-dose developmental effects and internal dosimetry.

Authors:  Madisa B Macon; LaTonya R Villanueva; Katoria Tatum-Gibbs; Robert D Zehr; Mark J Strynar; Jason P Stanko; Sally S White; Laurence Helfant; Suzanne E Fenton
Journal:  Toxicol Sci       Date:  2011-04-11       Impact factor: 4.849

4.  Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; H Puckett; J Oliver; G Nielsen; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2020-08-19       Impact factor: 4.219

5.  Physiologically based pharmacokinetic modeling of human exposure to perfluorooctanoic acid suggests historical non drinking-water exposures are important for predicting current serum concentrations.

Authors:  Rachel Rogers Worley; Xiaoxia Yang; Jeffrey Fisher
Journal:  Toxicol Appl Pharmacol       Date:  2017-07-03       Impact factor: 4.219

6.  The mammary gland is a sensitive pubertal target in CD-1 and C57Bl/6 mice following perinatal perfluorooctanoic acid (PFOA) exposure.

Authors:  Deirdre K Tucker; Madisa B Macon; Mark J Strynar; Sonia Dagnino; Erik Andersen; Suzanne E Fenton
Journal:  Reprod Toxicol       Date:  2014-12-12       Impact factor: 3.143

7.  Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia.

Authors:  Scott M Bartell; Antonia M Calafat; Christopher Lyu; Kayoko Kato; P Barry Ryan; Kyle Steenland
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

8.  Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages.

Authors:  Anne E Loccisano; Matthew P Longnecker; Jerry L Campbell; Melvin E Andersen; Harvey J Clewell
Journal:  J Toxicol Environ Health A       Date:  2013

9.  Hepatic carboxylesterases are differentially regulated in PPARα-null mice treated with perfluorooctanoic acid.

Authors:  Xia Wen; Angela A Baker; Curtis D Klaassen; J Christopher Corton; Jason R Richardson; Lauren M Aleksunes
Journal:  Toxicology       Date:  2019-01-24       Impact factor: 4.221

10.  Application of physiologically-based pharmacokinetic modeling to explore the role of kidney transporters in renal reabsorption of perfluorooctanoic acid in the rat.

Authors:  Rachel Rogers Worley; Jeffrey Fisher
Journal:  Toxicol Appl Pharmacol       Date:  2015-11-06       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.